Neovasc, partner of GADA and leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that JACC Cardiovascular Interventions published a peer reviewed article on the impact of Neovasc Reducer on ischemic burden and myocardial perfusion.  

A new study published on Circulation (Circulation.2019;139:337–346. DOI: 10.1161/CIRCULATIONAHA.118.038269), the outcomes of which have been presented at the AHA congress by prof. Navin K. Kapur (Tufts Medical Center), confirms efficiency and safety of Abiomed Impella CP on unloading the left ventricle in patients presenting with anterior ST-segment elevation myocardial infarction (STEMI) without cardiogenic shock. Trial

GADA Italia and Lifetech Scientific Corporation (LSC) have engaged with a long-time agreement for exclusive distribution over the whole national territory. LSC, established in 1999 in Shenzhen (People's Republic of China), is one of the most dynamic company in the development, production, and commercialization of minimally invasive interventional medical devices to treat cardiovascular diseases. Its

The Neovasc Reducer™ system is an implantable device, designed to create a permanent and controlled narrowing of the coronary sinus aimed at improving perfusion of ischemic regions in the myocardium in patients with reversible ischemic cardiomyopathy. The Reducer ™ is for use in patients, often defined "no options", who have refractory angina pectoris associated with

The magazine EuroIntervention (EuroIntervention 2018; Jaa-467 2018, doi: 10.4244/EIJ-D-18-00281) publishes encouraging results about safety and feasibility of traetment of bicuspid aortic valves with the TAVI aortic valve ACURATE neo (Boston Scientific). The outcomes have been collected by a multicenter retrospective and not randomized study about European experience of ACURATE neo in bicuspid (BAV) and tricuspid

Asaio Journal magazine publishes an article on the improvement of pulmonary arterial flow that the Abiomed Impella ventricular support contributes to generating in patients undergoing ECMO veno-arterial treatment (VA ECMO). Abiomed Impella Impella devices are devices for temporary ventricular support. The areas of application are both protection during high-risk percutaneous coronary interventional procedures (PCI), circulatory

The JACC-Cardiovascular Intervention published the 1-year outcomes of the perspective and multicentre SAVI-TF registry: in 25 European centers, 1000 patients are enrolled treated with transfemoral access by Boston Scientific's ACURATE neo valve (Logistic EuroSCORE II 6.6%). ACURATE neo ACURATE neo valve, composed of a self-expanding nitinol stent and porcine pericardial skirt, is designed in order